Manila Times Business
Parabilis Medicines Announces Pricing of Upsized Initial Public Offering
CAMBRIDGE, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines, Inc. (Nasdaq: PBLS) ("Parabilis”), a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease, today announced the pricing of its upsized initial public offering of 33,500,000 shares of its common stock at a price to the public of $20.00 per share. In addition, Parabilis has granted the un
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Bata, Django, De la Cruz lead coaching staff of new billiards NSA
2h ago
Tokenized Cash Management Advisory Group Publishes the Scope of Its Work Program
2h ago
COSMOBEAUTÉ MALAYSIA & BEAUTYEXPO 2026 RETURNS TO KLCC TO DRIVE B2B EXCELLENCE AND NEW BUSINESS FRONTIERS
2h ago
Regent Hong Kong Named Among First-Ever Winners of Condé Nast Traveler's Triple Crown Award
2h ago